Insulet Corp. Securities Litigation

On February 9, 2018, parties in the Insulet Corp. securities litigation reached an agreement to settle the case.  Plaintiffs alleged that Insulet misled investors about the success of a new insulin infusion pump system it launched in 2013 and manipulated a critical performance metric to mask declining new patient growth. Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided an expert report on market efficiency and whether damages can be computed for the Class.

Additional information is available here.